The data could revive the Alzheimer’s drug market to return its focus to amyloid plaques. Over the past few years, pharmaceutical companies have been wary to invest in treatments that exclusively factor amyloid plaque buildup after multiple trials failed to show promise.
Aduhelm, Biogen’s Alzheimer’s drug that spurred controversy after an FDA panel raised concerns about its efficacy, was designed to target amyloid plaque.
The narrative seems to be shifting again after Biogen’s shares rose 36 percent after the most recent trial data was released, according to the Journal.
Becker’s 3rd Annual Fall Chief Pharmacy Officer Summit is the top tier event that the people leading the future of pharmacy convene. This 3-day event is built specifically for Chief Pharmacy Officers and senior pharmacy leaders. The sessions examine the workforce, financial and clinical priorities shaping pharmacy today. Becker’s is where candid discussions flourish and new ideas thrive. Becker's 3rd Annual Fall Chief Pharmacy Officer Summit
